key: cord-0820604-w74nltsg authors: Bedin, Anne-Sophie; Makinson, Alain; Picot, Marie-Christine; Mennechet, Frank; Malergue, Fabrice; Pisoni, Amandine; Nyiramigisha, Esperance; Montagnier, Lise; Bollore, Karine; Debiesse, Ségolène; Morquin, David; Bourgoin, Penelope; Veyrenche, Nicolas; Renault, Constance; Foulongne, Vincent; Bret, Caroline; Bourdin, Arnaud; Le Moing, Vincent; Van de Perre, Philippe; Tuaillon, Edouard title: Monocyte CD169 expression as a biomarker in the early diagnosis of COVID-19 date: 2020-11-18 journal: J Infect Dis DOI: 10.1093/infdis/jiaa724 sha: bf6489e0fdf970174baec72bdf2776a77cfdd7eb doc_id: 820604 cord_uid: w74nltsg We assessed the expression of CD169, a type I interferon-inducible receptor, on monocytes (mCD169) in 53 adult patients admitted to the hospital during the COVID-19 outbreak for a suspicion of SARS-CoV-2 infection. mCD169 was strongly overexpressed in 30 out of 32 (93.7%) confirmed COVID-19 cases, compared to three out of 21 (14.3%) patients in whom the diagnosis of COVID-19 was finally ruled out. mCD169 was associated with the plasma interferon alpha level and thrombocytopenia. mCD169 testing may be helpful for the rapid triage of suspected COVID-19 patients during an outbreak. M a n u s c r i p t 2 Abstract: We assessed the expression of CD169, a type I interferon-inducible receptor, on monocytes (mCD169) in 53 adult patients admitted to the hospital during the COVID-19 outbreak for a suspicion of SARS-CoV-2 infection. mCD169 was strongly overexpressed in 30 out of 32 (93.7%) confirmed COVID-19 cases, compared to three out of 21 (14.3%) patients in whom the diagnosis of COVID-19 was finally ruled out. mCD169 was associated with the plasma interferon alpha level and thrombocytopenia. mCD169 testing may be helpful for the rapid triage of suspected COVID-19 patients during an outbreak. Keywords: SARS-CoV-2, Covid-19, CD169, Monocytes, viral infections A c c e p t e d M a n u s c r i p t 3 Early identification of COVID-19 and prompt diagnosis of SARS-CoV-2 infection are critical for care and prognosis during outbreaks. It is also mandatory to avoid unnecessary and time-consuming interventions for ruling out COVID-19 in patients with serious respiratory conditions requiring appropriate care. Type I interferons (IFN) are important factors for homeostasis of the immune response and play a key role in antiviral immunity. A robust type-I IFN response is critical in the early phase of SARS-CoV-2 infection to limit SARS-CoV-2 replication and avoid severe complications 1 . CD169, also known as sialoadhesin or Siglec-1, is constitutively expressed at low levels on monocytes, but its expression rises dramatically when monocytes become stimulated by IFNα and all other type I IFNs. Monocyte CD169 (mCD169) overexpression is associated with acute viral infections 2,3 . Furthermore, a subset of CD169 lung-resident macrophages that have immune-regulatory functions and proliferate after influenza infection has recently been described 4 . In March 2020, Montpellier University Hospital reorganized its emergency service delivery in response to the COVID-19 outbreak in order to facilitate triage, diagnosis and hospitalization of the patients presenting with suspected COVID-19. In this prospective observational study conducted during the COVID-19 outbreak, we evaluated mCD169 expression for the early identification of viral acute infection during SARS-CoV-2 epidemic in patients at hospital admission. This study was conducted by the University Hospital of Montpellier, during the peak of the COVID-19 epidemic between 15 March and 5 April 2020. It was approved by the accredited Institutional Table 1 ). Among the confirmed cases, 18 patients had a second cytometry analysis before being discharged from the hospital. The median age of the patients was 64 years (IQR, 51-78.5 years) and 54.7% were male (Sup. Table 2 ). 10 µl of EDTA sample was simultaneously lysed with 500 μL of Versalyse lysing solution and stained with CD64-CD169/infections dried custom mixture, composed of anti-CD169-phycoerythrin (PE) (clone 7-239) and anti-CD64-Pacific Blue (PB) (clone 22) (Sup. Fig.1 ). Results were expressed as CD169 monocyte/lymphocyte fluorescence ratio and CD64 neutrophils/lymphocytes fluorescence. A second panel was used containing CD45-FITC, CD8-ECD, CD3 PC5, CD4-RD1 (CYTO-STAT tetraCHROME) and CD38-PB. Samples were incubated at room temperature for 30 minutes, in the dark. All products or custom products came from Beckman Coulter Inc, (Brea, CA). We acquired on a 3-laser, 10-color Navios flow cytometer and analyzed using Kaluza Software version 2.1 (both from Beckman Coulter Brea, CA Inc). We assessed the expression of mCD169, nCD64 and CD38 bright on CD8 T-cells in 30 healthy controls to establish a threshold based on the median + 3SD. The thresholds were: 3.51 for the mCD169 MFI following the manufacturer's instructions. SARS-CoV-2 RNA was assessed using a RT-PCR targeting RNA-dependent RNA polymerase (RdRp) as previously described. Plasma samples were stored at − 80 °C until processing. Interferon alpha (IFN-α) was quantified using a multiplex microsphere assay (Invitrogen Human Inflammation 20-plex ProcartaPlex Panel, Marne-La-Vallée, France) on a Luminex apparatus (MAGPIX, Thermo Fisher Scientific, Massachusetts, USA) following manufacturer's instructions. Plasma samples were tested for IgG antibodies directed against SARS-CoV-2 nucleocapsid using a CEmarked ELISA (ID.Vet, ID screen® SARS-CoV-2-N, Montpellier, France) as previously described 5 . Each result is displayed as a ratio: S/P (Sample/positive control) expressed in percentile (%): S/P % = (Optic density (OD) of sample -OD negative control) / OD positive control -OD negative control) x 100. S/P > 40% is positive and < 40% is negative. Data were analysed and illustrated using Excel 2016 (Microsoft Corp, Redmond, Washington) and Prism 7 (GraphPad Software Inc, La Jolla, California) software. To determine statistical significance between the two groups (ie. CD169 COVID+ vs COVID -), unpaired Student's two-tailed t-test or nonparametric Mann-Whitney test was applied, according to the distribution of the data set. Correlations were analysed using Pearson or Spearman's rank test according of the normality of the data set. A c c e p t e d M a n u s c r i p t 6 A p value of <0.05 was considered statistically significant. There was a limit of 15 patients enrolled per day due to the limited capacity to include patients in the study. Among 162 patients admitted in the COVID-19 emergency unit from 15 March to 05 April 2020, 53 (32.7%) were included and tested for mCD169 expression. Thirty-two of these patients tested positive for SARS-CoV-2 RNA, and 21 tested negative. Thirty patients with a confirmed diagnosis of COVID-19 had a mCD169 expression level above the positivity threshold (93.7%) (Fig.1.A) . In contrast, only three of the 21 patients (14.3%) with a negative SARS-CoV-2 PCR result had a mCD169 overexpression. The level of mCD169 was inversely correlated with the CT (Cycle time detection) value of the SARS-CoV-2 PCR, suggesting that the immunological marker was slightly associated with the level of virus replication (R 2 = 0.24) (Fig.1.B) . At hospital admission, mCD169 was not associated with the duration, since the onset, of symptoms in COVID-19 confirmed patients (Sup. Fig.2.A) . Likewise, the level of mCD169 expression had no prognostic value as no differences were noted in patients who had to be admitted in intensive care units, patients with mild forms of COVID-19, or patients who died ( Fig.1.B) . IFNα concentration was significantly higher in COVID-19 confirmed patients compared to COVID-19 negative patients. (p<0.0001) ( Fig.1.D) . Overall, the mCD169 level was correlated with the concentration of IFN in plasma (r=0.48) (Sup. Fig.3 .F). The mCD169 expression level decreased in 15 out 18 confirmed COVID-19 patients, alongside IFNα, retested before they were discharged from the hospital (Sup. Fig.4 ). Of note, the platelet count increased between the first and second time points in all of the confirmed COVID-19 patients. The mCD169 level was also negatively correlated with the platelet count (r=-0.45) (Sup. Fig.3 .C), but no correlation was found with the CRP concentration, lymphocyte count or neutrophil count A c c e p t e d M a n u s c r i p t 7 (Sup. Fig.3. A.B.E) . To investigate whether mCD169 could complement serological testing, we retrospectively assessed anti-SARS-CoV-2 nucleocapsid IgG. Among the confirmed COVID-19 cases, seven patients also tested positive for SARS-CoV-2 IgG at the time of hospital admission. These patients had a lower mCD169 level than patients who tested negative for anti-SARS-CoV-2 IgG (p=0.0084), suggesting that high mCD169 may be associated with active SARS-CoV-2 infection, before seroconversion ( Fig.1.C) . Neutrophil CD64 (nCD64) was also assessed as a marker for systemic bacterial infection 3 . High nCD64 expression was observed in seven out of 21 (33.3%) SARS-CoV2 PCR negative patients (Sup. Fig.2.B) . Bacterial infection was microbiologically confirmed for all but one of these patients (6/7). Four out of 32 (12.5%) confirmed COVID-19 cases also had nCD64 expression above the threshold; two of them had confirmation of a bacterial infection. A higher median expression of CD38 bright on CD8+ T-cells also was observed in the COVID-19 confirmed group compared to the SARS-CoV2 uninfected group (Sup. Fig.2.C) . However, this marker has a limited capacity to identified COVID-19 cases since CD38 bright on CD8+ T-cells was at a normal level in 11 COVID-19 confirmed cases (34.3%). Nevertheless it shows a strong correlation with CD169 (r = 0.62) (Sup. Fig.3.D) . The test accuracy of mCD169 to predict COVID-19 infection during epidemic was studied by means of a receiver operating characteristic curve (ROC curve) and compared to the CRP level (Fig.2) . The sensitivity and specificity at the optimal operating point were 97% and 80%, respectively, with an AUC of 0.95. CRP had a sensitivity and specificity of 94% and 33%, respectively, with an AUC of 0.58. A c c e p t e d M a n u s c r i p t 8 The rapid identification of COVID-19 is a major challenge for emergency units, especially when a hospital has to cope with 200 to 300 suspected cases but a lower number of true SARS-CoV-2 infections. Montpellier University Hospital has been strongly impacted by the COVID-19 crisis although the region around Montpellier reported a relatively low proportion of COVID-19 cases during the first peak of the epidemic, which occurred in France between March and April 2020. Only a part of patients suspected of COVID-19 had confirmation of the infection. For the remainder, the diagnosis of COVID-19 needed to be rapidly ruled out following hospital admission. mCD169 may be a sensitive marker for the rapid triage of patients suspected of having COVID-19. Our observation on mCD169 overexpression in SARS-CoV-2 infected patients has been confirmed in other studies 6, 7, 8 . Type I IFNs induce the transcription of CD169 mRNA. Amplification of CD169 monocytes has been observed in other viral infections such as Zika, untreated HIV, and influenza 9, 10,11 . Hence, mCD169 may be a broad marker of viral infections. In this study, inclusions were carried out in March-April, whereas the influenza epidemic ended week 11 in France 12 . The value of this marker in a context of a COVID and influenza virus double epidemic need to be explored and compared. Overexpression appeared very early during COVID-19 but the dynamic of mCD169 remains to be explored. Patients tested negative for anti-SARS-CoV-2 had lower mCD169 compared to anti-SARS-CoV-2 positive patient. Likewise, a trend for a lower level of mCD169 was observed in patients with high CT value and low plasma IFN alpha concentration. These results suggest that the expression of the marker decreased over the course of the disease. SARS-CoV-2 infection elicits type I IFN production, considered as key contributor to early innate response against COVID-19 1 . Later in the disease course, impaired type I IFN production could be a characteristic of severe disease. As IFN-stimulated genes (ISGs), transcription of CD169 may be lower in severe COVID compared to middle forms of the disease. A trend for a lower mCD169 expression has been reported in COVID-19 confirmed patients hospitalized in intensive care unit 13 . In our study, A c c e p t e d M a n u s c r i p t 9 mCD169 at hospital admission was consistent across severity groups. The same observation was done using blood transcriptomes 14 and monocyte analysis 15 in patients with moderate versus severe COVID-19 outcomes. In conclusion, mCD169 is strongly overexpressed on monocytes during the early phase of the SARS- Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Increased Expression of CD169 on Blood Monocytes and Its Regulation by Virus and CD8 T Cells in Macaque Models of HIV Infection and AIDS Flow cytometry evaluation of infection-related biomarkers in febrile subjects in the emergency department Identification of a nerve-associated, lung-resident interstitial macrophage subset with distinct localization and immunoregulatory properties Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients A distinct innate immune signature marks progression from mild to severe COVID-19 An ultra-sensitive, ultra-fast whole blood monocyte CD169 assay for COVID-19 screening Mass cytometry and artificial intelligence define CD169 as a specific marker of SARS-CoV2-induced acute respiratory distress syndrome Comprehensive Immunoprofiling of Pediatric Zika Reveals Key Role for Monocytes in the Acute Phase and No Effect of Prior Dengue Virus Infection Monocyte and CD4+ T-cell antiviral and innate responses associated with HIV-1 inflammation and cognitive impairment CD64 and CD169 could help differentiate bacterial from viral infections in Emergency Department Bulletin épidémiologique grippe. Bilan de la surveillance Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19 Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 A c c e p t e d M a n u s c r i p t 11